Details for Patent: 8,501,698
✉ Email this page to a colleague
Which drugs does patent 8,501,698 protect, and when does it expire?
Patent 8,501,698 protects QTERNMET XR, XIGDUO XR, FARXIGA, QTERN, BYDUREON, BYDUREON PEN, and BYDUREON BCISE, and is included in six NDAs.
Protection for BYDUREON has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.
This patent has seventy-nine patent family members in thirty-two countries.
Summary for Patent: 8,501,698
Title: | Crystal structures of SGLT2 inhibitors and processes for preparing same |
Abstract: | The present invention relates to physical crystal structures of a compound of the formula I: ##STR00001## wherein R.sup.1, R.sup.2, R.sup.2a, R.sup.3 and R.sup.4 are as defined herein, especially ##STR00002## pharmaceutical compositions containing structures of compound I or II, processes for preparing same, intermediates used in preparing same, and methods of treating diseases such as diabetes using such structures. |
Inventor(s): | Gougoutas; Jack Z. (Princeton, NJ), Lobinger; Hildegard (Princeton, NJ), Ramakrishnan; Srividya (Princeton, NJ), Deshpande; Prashant P. (Princeton, NJ), Bien; Jeffrey T. (Princeton, NJ), Lai; Chiajen (Princeton, NJ), Wang; Chenchi (Princeton, NJ), Riebel; Peter (Princeton, NJ), Grosso; John Anthony (Princeton, NJ), Nirschl; Alexandra A. (Princeton, NJ), Singh; Janak (Princeton, NJ), DiMarco; John D. (Princeton, NJ) |
Assignee: | Bristol-Myers Squibb Company (Princeton, NJ) |
Application Number: | 13/049,712 |
Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for patent 8,501,698 |
Patent Claim Types: see list of patent claims | Composition; Compound; Use; |
Drugs Protected by US Patent 8,501,698
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Astrazeneca Ab | QTERNMET XR | dapagliflozin; metformin hydrochloride; saxagliptin hydrochloride | TABLET, EXTENDED RELEASE;ORAL | 210874-001 | May 2, 2019 | DISCN | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | Y | TREATMENT OF TYPE 2 DIABETES MELLITUS | ⤷ Try a Trial | |||
Astrazeneca Ab | QTERNMET XR | dapagliflozin; metformin hydrochloride; saxagliptin hydrochloride | TABLET, EXTENDED RELEASE;ORAL | 210874-002 | May 2, 2019 | DISCN | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | Y | TREATMENT OF TYPE 2 DIABETES MELLITUS | ⤷ Try a Trial | |||
Astrazeneca Ab | QTERNMET XR | dapagliflozin; metformin hydrochloride; saxagliptin hydrochloride | TABLET, EXTENDED RELEASE;ORAL | 210874-003 | May 2, 2019 | DISCN | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | Y | TREATMENT OF TYPE 2 DIABETES MELLITUS | ⤷ Try a Trial | |||
Astrazeneca Ab | QTERNMET XR | dapagliflozin; metformin hydrochloride; saxagliptin hydrochloride | TABLET, EXTENDED RELEASE;ORAL | 210874-004 | May 2, 2019 | DISCN | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | Y | TREATMENT OF TYPE 2 DIABETES MELLITUS | ⤷ Try a Trial | |||
Astrazeneca Ab | XIGDUO XR | dapagliflozin; metformin hydrochloride | TABLET, EXTENDED RELEASE;ORAL | 205649-005 | Jul 28, 2017 | RX | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | Y | TREATMENT OF TYPE 2 DIABETES MELLITUS | ⤷ Try a Trial | |||
Astrazeneca Ab | XIGDUO XR | dapagliflozin; metformin hydrochloride | TABLET, EXTENDED RELEASE;ORAL | 205649-002 | Oct 29, 2014 | RX | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | Y | TREATMENT OF TYPE 2 DIABETES MELLITUS | ⤷ Try a Trial | |||
Astrazeneca Ab | XIGDUO XR | dapagliflozin; metformin hydrochloride | TABLET, EXTENDED RELEASE;ORAL | 205649-001 | Oct 29, 2014 | RX | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | Y | TREATMENT OF TYPE 2 DIABETES MELLITUS | ⤷ Try a Trial | |||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 8,501,698
Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
---|---|---|---|---|---|
Argentina | 061730 | ⤷ Try a Trial | |||
Australia | 2007265246 | ⤷ Try a Trial | |||
Brazil | 122017015106 | ⤷ Try a Trial | |||
Brazil | 122017021516 | ⤷ Try a Trial | |||
Brazil | PI0713544 | ⤷ Try a Trial | |||
Canada | 2653344 | ⤷ Try a Trial | |||
Canada | 2924318 | ⤷ Try a Trial | |||
>Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |